LODIFLOZ
Live / Allowed — Published for opposition (as of 08 Sept 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 01 May 2026 filing date already counts against anyone who files later.
Record
- Serial number
- 99799124
- Mark type
- Stylized text
- Filed
- 01 May 2026
- Published for opposition
- 08 Sept 2026
- Attorney of record
- Jeffrey J. Scepanski
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for immunotherapy, cell therapy, and gene therapy for the treatment of autoimmune diseases and cancer; Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity
Owner
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US
Prosecution history
- 08 Sept 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Sept 2026 — PUBLISHED FOR OPPOSITION
- 02 Sept 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 Aug 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 29 Jul 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 28 Jul 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 28 Jul 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 01 Jul 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 01 Jul 2026 — NON-FINAL ACTION E-MAILED
- 01 Jul 2026 — NON-FINAL ACTION WRITTEN
- 29 Jun 2026 — ASSIGNED TO EXAMINER
- 01 May 2026 — APPLICATION FILING RECEIPT MAILED
- 01 May 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 01 May 2026 — NEW APPLICATION ENTERED